References
- Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis–critical steps for prevention and control. N Engl J Med. 2010;363(11):1–10.
- Raviglione MC, Smith IM. XDR tuberculosis–implications for global public health. N Engl J Med. 2007;356(7):656–659.
- World Health Organization. Multidrug and extensively drug resistant TB (M/XD-TB). Global report on surveillance and response. Geneva, Switzerland: WHO Press, World Health Organization; 2010. ( WHO/HTM/TB/2010.3).
- World Health Organization. Global tuberculosis report. Geneva, Switzerland: WHO Press, World Health Organization; 2013. (WHO/HTM/TB/2013.11).
- World Health Organization. Multidrug-resistant tuberculosis (MDR-TB). 2015. [ updated 2016]. Avaiable from: http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf
- European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe. 2016. Availalable from: http://ecdc.europa.eu/en/publications/publications/ecdc-tuberculosis-surveillance-monitoring-europe-2016.pdf
- Fattorini L, Mustazzolu A, Borroni E, et al. Italian multicentre study on resistance to antituberculosis drugs G: tuberculosis in migrants from 106 countries in Italy, 2008–2014. Eur Respir J. 2016;47(4):1273–1276.
- Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43(2):554–565.
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland: WHO Press, World Health Organization; 2016. (WHO/HTM/TB/2016.04).
- Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31(6):1155–1159.
- Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J. 2008;31(4):904–905.
- European Medicines Agency. Public assessment report: sirturo bedaquiline. London, UK: European Medicines Agency; 2013. (EMA/CHMP/329898/2013).
- Agenzia Italiana del Farmaco. Riclassificazione del medicinale per uso umano “Sirturo” (bedaquilina). Determina n.928, 2014. Gazzetta Ufficiale Serie Generale n.215 del 16-9-2014. Available from: http://www.gazzettaufficiale.it/eli/id/2014/09/16/14A07112/sg;jsessionid=0AAyS80OiMQ-P9g0raxVJA__.ntc-as2-guri2a
- Wolfson LJ, Walker A, Hettle R, et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015;10(3):e0120763.
- Diacon AH, Lounis N, Dannemann B. Multidrug-resistant tuberculosis and bedaquiline. N Engl J Med. 2014;371(25):2436.
- Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46(12):1844–1851.
- Lee J, Lim HJ, Cho YJ, et al. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2011;15(10):1331–1333.
- Tiemersma EW, van der Werf MJ, Borgdorff MW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601.
- Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari. Pharmacoecon Ital Res Art. 2009;11(2):83–93.
- Istituto Nazionale di Statistica. Mortality data of resident population. 2014. Available from: http://www.istat.it/it/archivio/mortalit%C3%A0
- Ministero della Salute. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Decreto 18/10/2012.; GU Serie Generale n.23 del 28-1-2013 - Suppl. Ordinario n. 8. Available from: http://www.gazzettaufficiale.it/eli/id/2013/01/28/13A00528/sg
- Ministero della Salute. La tubercolosi in Italia. 2008. [ updated 2016]. Avaiable from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1222_allegato.pdf
- Farmadati. Compendio Farmaceutico Telematico. 2015. [ updated 2016]. Avaiable from: http://www.farmadati.it/
- Organization for Economic Cooperation and Development. Annual Average Wage. 2014. [ updated 2016]. Avaiable from: https://stats.oecd.org/Index.aspx?DataSetCode=AV_AN_WAGE
- Banca d’Italia. Exchange rates archives daily publication and historical series. 2015. [ update 2015]. Available from: https://www.bancaditalia.it/compiti/operazioni-cambi/archivio-cambi/index.html?com.dotmarketing.htmlpage.language=1
- Working days calculator in Italy. 2014. [ updated 2016]. Avaiable from: www.giorni-lavorativi.com
- ISTAT. Unemployment rate of resident population. 2014. [ updated 2014]. Avaiable from: http://www.istat.it/en/labour-and-wages
- Hardinge FM, Black M, Chamberlain P, et al. TB contact tracing in South Buckinghamshire from 1994-mid to 1998. Am J Respir Crit Care Med. 1999;159(Suppl):A303.
- Ansari S, Thomas S, Campbell IA, et al. Refined tuberculosis contact tracing in a low incidence area. Respir Med. 1998;92(9):1127–1131.
- Jit M, Stagg HR, Aldridge RW, et al. Treat Evaluation Team: dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ. 2011;343:d5376.
- Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814–822.
- Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447–454.
- Messori A, Santarlasci B, Trippoli S, et al. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoecon Ital Res Art. 2003;5(2):53–67.
- Gunther G, Gomez GB, Lange C, et al. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J. 2015;45(4):1081–1088.
- Vassal A Cost-effectiveness of introducing bedaquiline in MDR-TB regimens—an exploratory analysis. 2013. [ updated 2016]. Available from: http://who.int/tb/challenges/mdr/CEA_bdqreport_final.pdf
- Diel R, Hittel N, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba to background regimens in Germany. Respir Med. 2015;109(5):632–641.
- Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63–80.
- Bocchino M, Greco S, Rosati Y, et al. Cost determinants of tuberculosis management in a low-prevalence country. Int J Tuberc Lung Dis. 2006;10(2):146–152.